Navigation Links
Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
Date:11/21/2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Trovagene, Inc.  (NASDAQ: TROV), a transrenal molecular diagnostic company, today announced the closing of a private placement consisting of 940,000 units at a purchase price of $4.00 per unit, with each unit consisting of one share of unregistered common stock and one warrant to purchase one share of common stock. The gross proceeds to Trovagene from this offering are approximately $3.76 million. The warrants are exercisable for five years from the date of closing at an exercise price of $5.32 per share.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Trovagene intends to use the net proceeds from this private placement offering to fund its research and development activities, and for working capital and other general corporate purposes.

"This private placement is well timed to provide Trovagene with sufficient capital to facilitate the availability of transrenal oncogene mutation testing to clinicians through our diagnostic laboratory," stated Antonius Schuh, Ph.D., chief executive officer of Trovagene.  "The Company now has cash in excess of $10 million, which we expect will be sufficient to fund our operations well into 2014."

This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities of the Company. The securities offered and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act and applicable state securities laws.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detec
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dr. Paul Billings joins Trovagenes Scientific Advisory Board
2. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
3. Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
4. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
5. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
6. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
7. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
8. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
9. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
10. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
11. Vasomedical Announces Financial Results for the Third Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... , March 29, 2015  Three-month paliperidone ... to relapse compared to placebo in patients with ... study published this week in the ... . Results of the study ... Drug Application (NDA) filing for three-month paliperidone palmitate ...
(Date:3/27/2015)... , March 27, 2015 BioCorRx, Inc. ( ... Santa Ana, California is a healthcare solutions organization, ... is estimated at $22 billion in the U.S. alone. The ... of FDA-approved Naltrexone in a specially compounded form for outpatient ... Australia and New Zealand ) ...
(Date:3/27/2015)... N.C. , March 27, 2015 Across ... essential to meeting challenges in clinical development, market education, ... tighter regulations, the Medical Affairs function is expected to ... mature markets. According to research by ... participants have a group dedicated to Medical Affairs. Among ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... Cephalon, Inc. (Nasdaq: CEPH ) announced ... BioAssets Development Corporation (BDC), following receipt of interim data ... administration of a tumor necrosis factor (TNF) inhibitor for ... a neuropathic inflammatory pain condition that occurs when the ...
... Harold Kaefer has been named Rhythmlink,s new director of ... medical device, diagnostic and laser industries, Mr. Kaefer will ... department. "Harold Kaefer has joined Rhythmlink as ... the company,s engineering team and direct its new product ...
Cached Medicine Technology:Cephalon Exercises its Option to Acquire BioAssets Development Corporation 2Cephalon Exercises its Option to Acquire BioAssets Development Corporation 3Cephalon Exercises its Option to Acquire BioAssets Development Corporation 4Rhythmlink International Announces Change in Engineering Management 2
(Date:3/29/2015)... IN (PRWEB) March 29, 2015 The culmination ... world is coming when the Final Four invades ... basketball tournament has been one filled with excitement, buzzer-beaters, and ... have been busted, superstars have been made, and future professional ... just be down to the four teams that advanced through ...
(Date:3/29/2015)... 2015 The Claudia Cohen Research ... announce today that Dr. Beth Y. Karlan has ... Cohen Research Foundation Prize for Outstanding Gynecologic Researcher. The ... Gynecologic Oncology 46th Annual Meeting on Women's Cancer in ... Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer ...
(Date:3/29/2015)... New York, NY (PRWEB) March 29, 2015 ... operators that conduct clinical trials and research, manage ... products to help their clients reach regulation standards. ... the pharmaceutical and medical device manufacturing sectors. Industry ... services, from early- to late-stage clinical research for ...
(Date:3/29/2015)... York, NY (PRWEB) March 29, 2015 ... treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) pending in the ... scheduled the litigation’s next Case Management Conference for ... that the meeting will address the progress of ... who allegedly experienced heart attacks, strokes and other ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Final Four Tickets: Ticket Down Slashes Kentucky Wildcats and Wisconsin Badgers Final Four Tickets at Lucas Oil Stadium and Issues Valuable Promo Code 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3
... Anderson Cancer Center suggest that the use of an anti ... tumor growth in the// human pancreas and also resulted in ... National Cancer Institute issued on Dec.20 reported that a combination ... effective than just the administration of chemotherapy agent gemcitabine. ...
... stress-relief by just holding her husband’s hand, says a study. ... that the institution of marriage// is losing ground. ... the University of Virginia, finds that women in a threatening ... hand and this has been observed in brain scans. ...
... cards from active members of the,British Lung Foundation, warning ... to Chronic Obstructive Pulmonary Disease (COPD) patients in Scotland. ... be set, to ensure patients received the best quality ... Disease is a term that refers to a number ...
... Testosterones can slow down the progression of Alzheimer's disease ... the primary male sex hormone, is one// in a ... , The findings, published in the December ... insight into the relationship between testosterone loss and AD, ...
... and keeping active to stay fit, old people especially those ... agile, if they just indulge// in brain exercises, to enhance ... in age, researchers said. ,Previous insights have indicated ... mind games. The study led by Sherry Willis, a human-development ...
... possible by Colonoscopy. More patients are willing to undergo this ... bud at the very onset. ,Cary Gross, ... University, found that there is a significant rise in colonoscopy ... in people .This has helped early treatment possible. ...
Cached Medicine News:Health News:Anti Allergy Drugs Reduce Tumor Growth 2Health News:Anti Allergy Drugs Reduce Tumor Growth 3Health News:Increase Testosterone Levels To Slow Down Alzheimer’ 2Health News:Colonoscopy Aids Early Detection of Colon Cancer 2
MRI curette, 8.5" overall length....
15" overall length, 5" handle....
10" overall length, 5" handle....
...
Medicine Products: